Novel Approaches for the Management of AL Amyloidosis
Purpose of Review
Light-chain-associated (AL) amyloidosis is a rare disease with a poor prognosis. However, we have made recent strides in more accurate diagnosis and effective treatment. Here, we discuss the most recent updates and advancements during the past year in the diagnosis, prognostication, and management of AL amyloidosis both in the upfront and relapsed setting.
New imaging modalities, such as cardiac magnetic resonance (CMR) and use of fluorine-labeled radiotracers, are emerging as an important diagnostic tool in conjunction with biomarkers in the diagnosis, prognosis, and monitoring of the effects of therapy. In addition, ongoing evaluation of plasma cell-directed therapeutics, including daratumumab, pomalidomide, and ixazomib, as well as promising targeted novel therapies, such as the monoclonal antibody NEOD001, are in development.
In conclusion, incorporating the use of plasma cell-directed therapy and novel agents targeting the amyloid deposits itself hold enormous potential in achieving improved outcomes in AL amyloidosis.
KeywordsAmyloid Biomarkers Systemic Plasma cell disorder Light chain type
Compliance with Ethical Standards
Conflict of Interest
Jonathan L. Kaufman is a consultant for Amgen, Abbvie, Takeda, Sutro, Roche, and Seattle Genetics. The authors declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
- 8.Dispenzieri A, Gertz MA, Saenger A, Kumar SK, Lacy MQ, Buadi FK, et al. Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin T. Am J Hematol. 2015;90(6):524–8.CrossRefPubMedGoogle Scholar
- 9.Andrikopoulou E, Bhambhvani P. Nuclear imaging of cardiac amyloidosis. J Nucl Cardiol. 2017;Google Scholar
- 11.Liu D, Hu K, Niemann M, Herrmann S, Cikes M, Stork S, et al. Effect of combined systolic and diastolic functional parameter assessment for differentiation of cardiac amyloidosis from other causes of concentric left ventricular hypertrophy. Circ Cardiovasc Imaging. 2013;6(6):1066–72.CrossRefPubMedGoogle Scholar
- 15.Cappelli F, Gallini C, di Mario C, Costanzo EN, Vaggelli L, Tutino F, et al. Accuracy of 99mTc-Hydroxymethylene diphosphonate scintigraphy for diagnosis of transthyretin cardiac amyloidosis. J Nucl Cardiol. 2017;Google Scholar
- 21.Sanchorawala V, et al. Safety and tolerability of daratumumab in patients with relapsed light chain (AL) amyloidosis: preliminary results of a phase II study. Blood. 2017;130Google Scholar
- 22.Roussel M, et al. A prospective phase II of daratumumab in previously-treated systemic light chain (AL) amyloidosis. Blood. 2017;130Google Scholar
- 30.Kumar S, et al. Doxycycline used as post transplant antibacterial prophylaxis improves survival in patients with light chain amyloidosis undergoing autologous stem cell transplantation. Blood. 2012;120Google Scholar
- 31.D'Souza A, M.e.a. Rationale and design of DUAL study: Doxycycline to Upgrade response in light chain (AL) amyloidosis (DUAL): a phase 2 pilot study of a two-pronged approach of prolonged doxycycline with plasma cell-directed therapy in the treatment of AL amyloidosis. Contemp Clin Trials, 2017; 8: 33–38.Google Scholar
- 32.Chari, A.et al. Subcutaneous delivery of daratumumab in patients (pts) with relapsed or refractory multiple myeloma (RRMM): Pavo, an open-label, multicenter, dose escalation phase 1b study. 2017.Google Scholar
- 35.Kaufman J, et al. Phase 1 study of venetoclax in combination with dexamethasone as targeted therapy for t(11;14) relapsed/refractory mulitple myeloma, in ASH. Atlanta, GA.Google Scholar
- 41.Edwards CV, et al. Final analysis of the phase 1a/b study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with relapsed or refractory AL amyloidosis. Blood. 2017;130Google Scholar